Skip to content
PubMed This is a summary of 31 peer-reviewed journal articles Updated
Pediatric Hepatology

Congenital Bile Acid Synthesis Defect Type 1: A Patient Guide

At a Glance

CBAS1 (HSD3B7 deficiency) causes bile buildup, jaundice, and poor growth because the liver cannot make the bile acids needed for digestion. Early cholic acid replacement can improve nutrient absorption and liver health, while advanced scarring may require transplant evaluation.

Congenital Bile Acid Synthesis Defect Type 1 (CBAS1), also known as HSD3B7 deficiency, is an extremely rare genetic condition that changes how the liver processes the building blocks of digestion. In a healthy body, the liver creates primary bile acids, which act like biological detergents to help emulsify and absorb fats and fat-soluble vitamins, while also flushing out waste. In children with CBAS1, a missing enzyme (the HSD3B7 protein) creates a metabolic roadblock, preventing the liver from completing this vital process [1]. This leads to a dual challenge: the body cannot absorb essential fats and vitamins, and the liver struggles as abnormal, alternative bile acids are produced and accumulate [2].

Infants with this condition typically show signs of cholestasis (a backup of bile), which often appears as persistent yellowing of the skin and eyes (jaundice) [3]. Over time, parents may also notice that their child is struggling to gain weight or grow at a normal rate [4]. Identifying this condition can be tricky because it often lacks the high markers of liver stress (such as a high GGT level) that doctors expect to see in other neonatal liver diseases [5]. Finding this unique “laboratory fingerprint” of low or normal GGT alongside low or normal serum bile acids is a critical clue [2].

The most vital thing for a family to know is that CBAS1 has a specific, targeted treatment. By using primary bile acid replacement therapy (such as cholic acid), doctors provide the body with the exact acids it is unable to make on its own [6]. This treatment helps satisfy the body’s need for nutrients while signaling the liver to stop producing the abnormal acids [7].

Many children respond very well to early treatment, with stabilized liver health and improved development. However, outcome depends heavily on the age at treatment, any existing liver scarring (fibrosis or cirrhosis), and adherence to the regimen; some children with advanced disease may still require liver transplant evaluation [8][9].

What You Need to Do Now

  • Confirm Your Team: Ensure your child is being evaluated by a pediatric hepatologist and a biochemical geneticist.
  • Understand Instructions: Obtain exact administration guidelines for bile acid therapy (Cholbam) and prescribed vitamin supplements. Do not alter doses independently.
  • Emergency Plan: Know the after-hours contact number for your specialist team and learn the red-flag symptoms for bleeding and infant distress.
  • Prepare Records: Gather your child’s complete lab history, urine mass spectrometry results, and genetic reports for your specialist visits.

Common questions in this guide

What is congenital bile acid synthesis defect type 1 (CBAS1)?
CBAS1, also called HSD3B7 deficiency, is a rare genetic condition in which the liver cannot complete production of primary bile acids. This can cause bile to build up in the liver and make it harder for the body to absorb fats and fat-soluble vitamins.
What signs might suggest CBAS1 in a baby?
Persistent jaundice and cholestasis, or a backup of bile, are common early clues. Poor weight gain or growth may also occur, especially when the condition is not recognized and treated.
How do doctors look for CBAS1?
Doctors may suspect CBAS1 when an infant has cholestasis with low or normal GGT and low or normal serum bile acids. They may also review urine mass spectrometry results and genetic reports as part of the specialist evaluation.
What treatment is used for HSD3B7 deficiency?
Primary bile acid replacement, such as cholic acid (Cholbam), gives the body the bile acids it cannot make and can reduce production of abnormal bile acids. Prescribed vitamin supplements may also be needed, and caregivers should follow specialist dosing instructions without changing doses themselves.
Can early treatment improve a child's outlook with CBAS1?
Many children improve with early treatment, including more stable liver health and better development. Outlook depends on age at treatment, existing liver scarring such as fibrosis or cirrhosis, and adherence; children with advanced disease may need liver transplant evaluation.
Which specialists should care for a child with CBAS1?
A pediatric hepatologist and a biochemical geneticist are important members of the evaluation team. They can help confirm the diagnosis, interpret laboratory and genetic information, and guide bile acid therapy and monitoring.

Get notified when new evidence is published on Congenital bile acid synthesis defect type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (9)
  1. 1

    Substrate specificity and kinetic mechanism of 3β-hydroxy-Δ5-C27-steroid oxidoreductase.

    Gardner SM, Vogt A, Penning TM, Marmorstein R

    The Journal of biological chemistry 2024; (300(12)):107945 doi:10.1016/j.jbc.2024.107945.

    PMID: 39505210
  2. 2

    [Infant with 3β-hydroxy-Δ(5)-C27 steroid dehydrogenase deficiency: report of two cases and literatures review].

    Li X, Huang Z, Wang H

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2015; (53(5)):360-5.

    PMID: 26080666
  3. 3

    Bile Acid Synthesis Disorder Masquerading as Intractable Vitamin D-Deficiency Rickets.

    Ahmad O, Nogueira J, Heubi JE, et al.

    Journal of the Endocrine Society 2019; (3(2)):397-402 doi:10.1210/js.2018-00314.

    PMID: 30746501
  4. 4

    Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis.

    Heubi JE, Setchell KDR

    Journal of pediatric gastroenterology and nutrition 2020; (70(4)):423-429 doi:10.1097/MPG.0000000000002618.

    PMID: 31899729
  5. 5

    Inborn errors of bile acid metabolism in Japan.

    Mizuochi T, Takei H, Nittono H, Kimura A

    Pediatrics international : official journal of the Japan Pediatric Society 2023; (65(1)):e15490 doi:10.1111/ped.15490.

    PMID: 36704863
  6. 6

    Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood.

    Gonzales E, Matarazzo L, Franchi-Abella S, et al.

    Orphanet journal of rare diseases 2018; (13(1)):190 doi:10.1186/s13023-018-0920-5.

    PMID: 30373615
  7. 7

    Tandem mass spectrometric determination of atypical 3β-hydroxy-Δ5-bile acids in patients with 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency: application to diagnosis and monitoring of bile acid therapeutic response.

    Zhang W, Jha P, Wolfe B, et al.

    Clinical chemistry 2015; (61(7)):955-63 doi:10.1373/clinchem.2015.238238.

    PMID: 25931455
  8. 8

    Atypical clinical presentation and successful treatment with oral cholic acid of a child with defective bile acid synthesis due to a novel mutation in the HSD3B7 gene.

    Bossi G, Giordano G, Rispoli GA, et al.

    Pediatric reports 2017; (9(3)):7266 doi:10.4081/pr.2017.7266.

    PMID: 29081931
  9. 9

    Genetic spectrum and clinical characteristics of 3β-hydroxy-Δ5-C27-steroid oxidoreductase (HSD3B7) deficiency in China.

    Zhao J, Setchell KDR, Gong Y, et al.

    Orphanet journal of rare diseases 2021; (16(1)):417 doi:10.1186/s13023-021-02041-7.

    PMID: 34627351

This page is for informational purposes only and does not constitute medical advice. Your child's pediatric hepatologist and biochemical geneticist should interpret test results and guide treatment.